Your browser doesn't support javascript.
A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.
Natori, Yoichiro; Martin, Eric; Mattiazzi, Adela; Arosemena, Leopoldo; Ortigosa-Goggins, Mariella; Shobana, Sivan; Roth, David; Kupin, Warren Lee; Burke, George William; Ciancio, Gaetano; Morsi, Mahmoud; Phancao, Anita; Munagala, Mrudula R; Butrous, Hoda; Manickavel, Suresh; Sinha, Neeraj; Sota, Katherine; Pallikkuth, Suresh; Bini, Julia; Simkins, Jacques; Anjan, Shweta; Vianna, Rodrigo M; Guerra, Giselle.
  • Natori Y; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Martin E; Division of Infectious Disease, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Mattiazzi A; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Arosemena L; Division of Hepatology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Ortigosa-Goggins M; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Shobana S; Division of Nephrology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Roth D; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Kupin WL; Division of Hepatology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Burke GW; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Ciancio G; Division of Nephrology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Morsi M; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Phancao A; Division of Nephrology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Munagala MR; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Butrous H; Division of Nephrology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Manickavel S; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Sinha N; Division of Nephrology, Department of Medicine, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Sota K; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Pallikkuth S; Department of Surgery, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Bini J; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Simkins J; Department of Surgery, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Anjan S; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
  • Vianna RM; Department of Surgery, Miller School of Medicine Miami, University of Miami, Miami, FL, United States.
  • Guerra G; Miami Transplant Institute, Jackson Health System, Miami, FL, United States.
Transpl Int ; 36: 10938, 2023.
Article in English | MEDLINE | ID: covidwho-2300766
ABSTRACT
Solid Organ Transplant (SOT) recipients are at significant higher risk for COVID-19 and due to immunosuppressive medication, the immunogenicity after vaccination is suboptimal. In the previous studies, booster method showed significant benefit in this population. In the current study, we compared using a mix-and-match method vs. same vaccine as a third dose in SOT recipients. This was a patient-blinded, single center, randomized controlled trial comparing BNT162b2 vs. JNJ-78436735 vaccine as the third dose after two doses of BNT162b2 vaccine. We included adult SOT recipients with functional graft who had received two doses of BNT162b2 vaccine. Participants were randomly assigned to receive either BNT162b2 or JNJ-78436735 in one-to-one ratio. Primary outcome was SARS-CoV-2 IgG positivity at 1 month after the third dose. Sixty SOT recipients, including 36 kidney, 12 liver, 2 lung, 3 heart, and 5 combined transplants, were enrolled, and 57 recipients were analyzed per protocol. There were no statistically significant differences between the two vaccine protocols for IgG positivity (83.3% vs. 85.2% for BNT162b2 and JNJ-78436735, respectively, p = 0.85, Odds Ratio 0.95, 95% Confidence Interval 0.23-4.00). Comparison of the geometric mean titer demonstrated a higher trend with BNT162b2 (p = 0.09). In this pilot randomized controlled trial comparing mix and match method vs. uniform vaccination in SOT recipients, both vaccines were safely used. Since this was a small sample sized study, there was no statistically significant difference in immunogenicity; though, the mix and match method showed relatively lower geometric mean titer, as compared to uniform vaccine. Further studies need to be conducted to determine duration of this immunogenicity. Clinical Trial Registration https//clinicaltrials.gov/ct2/show/NCT05047640?term=20210641&draw=2&rank=1, identifier 20210641.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / Organ Transplantation / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Language: English Journal: Transpl Int Journal subject: Transplantation Year: 2023 Document Type: Article Affiliation country: Ti.2023.10938

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / Organ Transplantation / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Language: English Journal: Transpl Int Journal subject: Transplantation Year: 2023 Document Type: Article Affiliation country: Ti.2023.10938